Kona snags ex-SonoSite exec to helm renal denervation

Washington's Kona Medical has millions in venture cash and a novel approach to renal denervation, and now the startup has recruited an ultrasound expert to lead its development efforts.

Kona has appointed Jim Gilmore, a co-founder of point-of-care ultrasound outfit SonoSite, to lead as senior vice president and oversee the development of Surround Sound, the company's renal denervation system. Gilmore led SonoSite's R&D efforts until Fujifilm bought the company for $995 million in 2011, and his career in ultrasound technologies includes stops at GE Healthcare ($GE) and Diasonics.

Now Gilmore is tasked with leading commercial product development of Surround Sound, a noninvasive device designed to ablate nerves in the renal artery through focused ultrasound.

In its latest trial, Surround Sound patients reported an average 29-mmHg drop in systolic blood pressure after 6 months and endured no device-related serious adverse events, results that put the device in the same ballpark as catheter-based offerings from the likes of Medtronic ($MDT), Boston Scientific ($BSX) and Covidien ($COV).

The company hauled in $40 million in December to develop its tech, a round led by "a large medical device company," Kona said, leaving it at that.

Analysts believe the market for renal denervation could swell to around $3 billion worldwide in the next decade, and Kona is among at least three devicemakers developing noninvasive, ultasound-based treatments for hypertension. ReCor Medical, based out of California, is the farthest along with its CE-marked Paradise system, while Israel's Cardiosonic is in the midst of raising $16.1 million to develop a device called Tivus.

No renal denervation system, ultrasound or otherwise, has been approved by the FDA.

- read Kona's announcement

Special Report: Fujifilm/Sonosite - Top 10 Medical Device Deals of 2011

Suggested Articles

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.